Leflunomide
- Generic Name
- Leflunomide
- Brand Names
- Arava, Leflunomide medac, Leflunomide Zentiva (previously Leflunomide Winthrop), Leflunomide ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 75706-12-6
- Unique Ingredient Identifier
- G162GK9U4W
- Background
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
- Indication
For the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
- Associated Conditions
- Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis
- Associated Therapies
- -
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Deborah Doroshow
- Target Recruit Count
- 24
- Registration Number
- NCT04997993
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 114
- Registration Number
- NCT04737343
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳AnHui provincial hospital, Hefei, Anhui, China
🇨🇳the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China
CHronic Nonbacterial Osteomyelitis International Registry
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT04532372
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT04508790
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT04463615
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT04370483
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Leflunomide in Mild COVID-19 Patients
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 11
- Registration Number
- NCT04361214
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2019-12-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT04212416
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.